林欣

邮箱: linxin307@tsinghua.edu.cn

电话: +86-10-62794262

研究方向:

林欣教授的研究工作致力于揭示免疫细胞激活的调控的分子机制，以及肿瘤的细胞免疫治疗研究方法。研究团队在免疫细胞激活的机制研究方面发表了一系列高水平的研究论文。并根据T淋巴细胞激活机制设计TCR受体为基础的新型CAR-T细胞治疗方法，相关的CAR-T/TCR-T细胞治疗产品已经进入早期临床试验应用于肿瘤患者的免疫治疗

代表性科研论文:

1.Zhao X, Guo Y, Jiang C, Chang Q, Zhang S, Luo T, Zhang B, Jia X, Hung MC, Dong C, Lin X (2017) JNK1 negatively controls antifungal innate immunity by suppressing CD23 expression. Nat Med. 2017 Mar;23(3):337-346. doi: 10.1038/nm.4260. Epub 2017 Jan 23.

2.Xu X, Xu J, Zheng G, Lu H, Rui W, Guan J, Cheng L, Yang D, Wang M, Duan J, Lv Q, Li J, Zhao X, Chen C, Shi P, Jia X, Lin X. (2018). CARD9S12N mutation converts alveolar macrophages into IL-5-producing cells and facilitates type 2 immune responses. Nat Immunol, 2018 Jun;19(6):547-560.

3.Wang M, Zhang S, Zheng G, Huang J, Songyang Z, Zhao X, Lin X. (2018). Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A. Immunity. 2018 Jul 17;49(1):66-79

4.Wang T, Fan C, Yao A, Xu X, Zheng G, You Y, Jiang C, Zhao X, Hung MC, Lin X. (2018). The adaptor protein CARD9 protects against colitis-associated colon cancer by restricting mycobiota-mediated expansion of myeloid-derived suppressor cells. Immunity, 2018 Sep 18;49(3):504-514

5.Tang Y, Tu H, Zhang J, Zhao X, Lin X (2019). K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. Nat Commun. 2019 Sep 13;10(1):4157.

6.Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, Dong J, Zhao X, and Lin X (2020) CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Euro J Immunol. 2020 May;50(5):712-724

7.Liu Y, Liu G, Wang J, Zheng Z, Jia L, Rui W, Huang D, Zhou Z, Zhou L, Wu X, Song Lin S, Zhao X, Lin X (2021) Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med. 2021 Mar 24;13(586).